Click here for slides on this topic


Glucose homeostasis

Maintenance of a steady but not excessive supply of glucose using mechanisms that regulate the appearance/disappearance of glucose in the bloodstream.


The following content matched the glossary term: Glucose homeostasis

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes

Top

Defronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP 4 inhibitor alogliptin combined with pioglitazone, in metformin treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012 Mar 14. Epub ahead of print. Optimal management of type 2 diabetes remains an elusive goal. Combination therapy addressing the core defects of impaired insulin secretion and insulin resistance shows promise in maintaining glycemic control.

Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes

Top

Hardman TC, Dubrey SW. Development and potential role of type 2 sodium glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther. 2011;2(3):133-145. There is a recognized need for new treatment options for type 2 diabetes mellitus (T2DM). Recovery of glucose from the glomerular filtrate represents an important mechanism in maintaining glucose homeostasis and represents a novel target for the management of T2DM.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes

Top

Jellinger PS. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Postgrad Med. 2011 Jan;123(1):53-65. Glucose homeostasis is regulated by a complex interaction of hormones, principally including insulin, glucagon, amylin, and the incretins. Glucagon, cortisol, catecholamines, and growth hormone serve as the classic glucose counterregulatory hormones.

Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists

Top

Schondorf T, Lubben G, Karagiannis E, Erdmann E, Forst T, Pfutzner A. Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study. Diab Vasc Dis Res. 2010;7(2):145-150. Patients with diabetes mellitus and IGT have a high risk for cardiovascular events. It is tempting to speculate that these patients are often first seen by cardiologists.

Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists

Top

Hansen KB, Knop FK, Holst JJ, Vilsbøll T. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int J Clin Pract. 2009;63(8):1154-1160. The incretin system is an area of great interest for the development of new therapies for the management of type 2 diabetes. Existing antidiabetic drugs are often insufficient at getting patients to glycaemic goals.

Efficacy & safety of human glucagon-like peptide-1 analog liraglutide in combination w/ metformin & TZD in patients w/ type2 diabetes (LEAD-4 Met+TZD)

Top

Zinman B, Gerich J, Buse JB, et al, for the LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32(7):1224-1230. OBJECTIVE: To determine the efficacy and safety of liraglutide (a glucagon-like peptide-1 receptor agonist) when added to metformin and rosiglitazone in type 2 diabetes.

Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents

Top

Kohnert KD, Augstein P, Zander E, et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care. 2009;32(6):1058-1062. Glucose fluctuations trigger activation of oxidative stress, a main mechanism leading to secondary diabetes complications. We evaluated the relationship between glycemic variability and beta-cell dysfunction.

Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population

Top

Shigetoh Y, Adachi H, Yamagishi S, et al. Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. Am J Hypertension.. 2009;22(2):151-155. Emerging evidence indicates an association between sympathetic activation and metabolic syndrome. However, sympathetic activation in metabolic syndrome may be a cause, consequence, or just epiphenomenon.

Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes

Top

McGill JB. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Postgrad Med. 2009;121(1):46-58. Glucose homeostasis is governed by a complex interplay of hormonal signaling and modulation. Insulin, glucagon, amylin, the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and other hormones and enzymes interact to maintain glucose homeostasis and normal cellular metabolism. 

Pioglitazone vs glimepiride: differential effects on vascular endothelial function in patients with type 2 diabetes

Top

Papathanassiou K, Naka KK, Kazakos N, et al. Pioglitazone vs glimepiride: differential effects on vascular endothelial function in patients with type 2 diabetes. Atherosclerosis. 2008 Dec 6. [Epub ahead of print]. The aim of this study was to compare the effect of glimepiride and pioglitazone on endothelial function in patients with type 2 diabetes already on metformin.

1 2 3 4 Next 

Slide Library Results

Search Results for: Glucose homeostasis Slides Found: 2
SGLT Glucose Homeostasis Diabetes Education Slides | NDEI
Metabolic Surgery for Type 2 Diabetes Treatment Guidelines PPT | NDEI